Nurix Therapeutics-This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

公司与罗氏达成合作协议 - Nurix Therapeutics与罗氏达成协议，共同商业化其领先资产bexobrutideg [1] 核心资产 - 协议涉及的核心资产是Nurix Therapeutics的领先候选药物bexobrutideg [1]

Nurix Therapeutics-This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug - Reportify